GSK plc ADRhedgedGSKH

GSK plc ADR-hedged ETF, ticker GSKH, opened for business on Nasdaq on 15 July 2026 with the promise of “global healthcare access without the pound’s tantrums.” The fund’s mandate is simple: hold the GSK ADR and hedge the daily sterling moves using short-dated FX futures. What investors actually get is one stock wrapped in filing trail and a fee that eats any FX benefit before the first dividend lands. The issuer’s marketing deck shows a green healthcare icon superimposed on a globe, while the EDGAR filing quietly states the top holding is 100% GSK ADR, concentration risk included. The fund’s expense ratio is 0.45% plus an embedded hedging cost that FINRA’s analyzer flags as “above peer,” pushing the all-in drag toward 0.67% per year. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/gskh)

The wrapper’s selling line-“currency-hedged access to GSK”-masks two realities. First, the fund is not a basket; it is a single ADR plus a futures strip. Second, the futures strip is a weekly roll whose cost can spike when sterling gaps, a detail absent from the prospectus headline. The issuer’s website still claims “broad healthcare exposure,” but the EDGAR filing reveals the fund’s diversification is limited to the ADR’s sector label, not its holdings. Investors who rely on the marketing slide deck for colour will miss the fact that the fund’s liquidity is polite: average daily volume is $1.2 million and the quoted spread is 35 bps, wide enough to swallow a modest retail ticket. (source: SEC EDGAR fund search for GSKH, https://www.sec.gov/edgar/search/#/q=GSKH)

The issuer’s latest EDGAR filing, dated 30 June 2026, supplies no live performance numbers, only the structure, fees, and hedging method. FINRA’s fund analyzer confirms the hedging cost is material, but the tool cannot display the fund’s tracking error versus the hedged ADR because the live results are not yet filed. The prospectus reserves the right to alter hedging frequency and to substitute futures contracts, giving the issuer an escape hatch that reads like a bank’s get-out-of-jail clause. In short, GSKH’s marketing sells a story, the fund delivers a single stock plus a fee, and the regulatory filings do not yet reveal how the hedging actually performs in the wild. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

TradingView shows GSKH’s price quoted on Nasdaq only, with no cross-listing or dark-pool context, so any spread analysis must stay on the primary venue. The fund’s first-month volume suggests modest enthusiasm rather than momentum, and the lack of historical returns in the filings means any back-test must be treated as hypothetical. Until the issuer files a performance history or a live tracking error, the wrapper’s true cost and tracking fidelity remain unproven. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/gskh)

What changed this week: Nasdaq now lists GSKH with daily liquidity of roughly $1.2 m and a 35 bps spread, while the issuer’s website still advertises “global healthcare access” without disclosing the single-stock dependence. The EDGAR filing is current on structure and fees but silent on live returns, and FINRA’s analyzer flags the hedging drag without quantifying it live. Evidence gap: no live performance history, no quarterly tracking error, no live hedging cost delta versus the ADR. Evidence needed: a performance table in the next filing and a live tracking error metric in the issuer’s marketing. (source: EDGAR, https://www.sec.gov/edgar/search/#/q=GSKH)